Technical Analysis for MORF - Morphic Holding, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Fell Below 20 DMA | Bearish | 6.59% | |
| Bollinger Band Squeeze | Range Contraction | 6.59% | |
| Gapped Up | Strength | 6.59% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 15 hours ago |
| Rose Above Upper Bollinger Band | about 15 hours ago |
| Up 5% | about 15 hours ago |
| Upper Bollinger Band Resistance | about 15 hours ago |
| Up 2 ATRs | about 15 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/31/2024
Morphic Holding, Inc., a biopharmaceutical company, focuses on the discovery and development of oral small-molecule integrin therapeutics. The company's lead product candidates in clinical development are MORF-720, a selective oral avb6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis; and a4b7 specific integrin inhibitors for the treatment of inflammatory bowel disease. Its product candidates in discovery stage include an avb1 integrin for the treatment of fibrosis; two TGF-b activations for gastrointestinal cancers and fibrosis; and other aI domain integrins. The company was founded in 2014 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Development Molecular Biology Gastrointestinal Inflammatory Bowel Disease Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Fibrosis Gastrointestinal Cancer Treatment Of Fibrosis Treatment Of Idiopathic Pulmonary Fibrosis Treatment Of Inflammatory Bowel Disease Integrin
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Development Molecular Biology Gastrointestinal Inflammatory Bowel Disease Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Fibrosis Gastrointestinal Cancer Treatment Of Fibrosis Treatment Of Idiopathic Pulmonary Fibrosis Treatment Of Inflammatory Bowel Disease Integrin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 63.0825 |
| 52 Week Low | 19.345 |
| Average Volume | 393,037 |
| 200-Day Moving Average | 33.39 |
| 50-Day Moving Average | 31.12 |
| 20-Day Moving Average | 28.66 |
| 10-Day Moving Average | 29.34 |
| Average True Range | 1.38 |
| RSI (14) | 54.34 |
| ADX | 22.75 |
| +DI | 22.98 |
| -DI | 21.23 |
| Chandelier Exit (Long, 3 ATRs) | 26.85 |
| Chandelier Exit (Short, 3 ATRs) | 30.49 |
| Upper Bollinger Bands | 30.46 |
| Lower Bollinger Band | 26.86 |
| Percent B (%b) | 0.94 |
| BandWidth | 12.56 |
| MACD Line | -0.37 |
| MACD Signal Line | -0.65 |
| MACD Histogram | 0.2716 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 33.01 | ||||
| Resistance 3 (R3) | 32.95 | 31.96 | 32.54 | ||
| Resistance 2 (R2) | 31.96 | 31.26 | 31.99 | 32.39 | |
| Resistance 1 (R1) | 31.10 | 30.82 | 31.53 | 31.16 | 32.23 |
| Pivot Point | 30.11 | 30.11 | 30.33 | 30.14 | 30.11 |
| Support 1 (S1) | 29.25 | 29.41 | 29.68 | 29.31 | 28.23 |
| Support 2 (S2) | 28.26 | 28.97 | 28.29 | 28.07 | |
| Support 3 (S3) | 27.40 | 28.26 | 27.92 | ||
| Support 4 (S4) | 27.46 |
